Yitangkang decoction in the treatment of glomerular filtration barrier damage through AMPKα1/ZDHHC8/SLC7A11/GPX4 and TGF-β/Smad signaling pathways: A multi-omics analysis - PubMed
6 hours ago
- #Multi-omics
- #Ferroptosis
- #Diabetic kidney disease
- Yitangkang decoction (YTK) shows potential in treating glomerular filtration barrier damage in diabetic kidney disease (DKD).
- YTK works through multiple pathways including AMPKα1/ZDHHC8/SLC7A11/GPX4 and TGF-β/Smad signaling.
- Multi-omics analysis reveals YTK's mechanisms: inhibiting TGF-β/Smad pathway, enhancing SLC7A11 palmitoylation, modulating macrophage polarization, and providing multi-target cytoprotection.
- YTK reduces urinary albumin-to-creatinine ratio (UACR), serum creatinine, urea, uric acid, and lipid peroxide levels while restoring glutathione levels.
- Key active components puerarin and quercitrin bind directly to GPX4 and TGF-β1, mediating YTK's therapeutic effects.
- YTK represents a promising multi-target therapeutic strategy for DKD by balancing injury and protective signaling pathways.